Activity
-
I am honored to join such a talented team of professionals dedicated to patients and the retina community. I look forward to continuing to support…
I am honored to join such a talented team of professionals dedicated to patients and the retina community. I look forward to continuing to support…
Liked by Lane Weaver
-
What a great trip to Chicago! As we advance into the clinic, I loved being back on stage at a scientific conference, speaking for the first time on…
What a great trip to Chicago! As we advance into the clinic, I loved being back on stage at a scientific conference, speaking for the first time on…
Liked by Lane Weaver
-
Two developments in the longevity space caught my eye this week: Bioage and sleep. 1) Bioage is cleverly reframing the value of a longevity-focused…
Two developments in the longevity space caught my eye this week: Bioage and sleep. 1) Bioage is cleverly reframing the value of a longevity-focused…
Liked by Lane Weaver
Experience
-
-
-
-
-
-
-
-
-
-
-
Education
Licenses & Certifications
More activity by Lane
-
I'm proud to share that Ansa Biotechnologies, Inc. synthesized the DNA template for Sid Sijbrandij's mRNA-based personalized cancer vaccine. This is…
I'm proud to share that Ansa Biotechnologies, Inc. synthesized the DNA template for Sid Sijbrandij's mRNA-based personalized cancer vaccine. This is…
Liked by Lane Weaver
-
When my mother’s breast cancer returned as metastatic while I was a young mother myself, I experienced the stretch of caring for two generations at…
When my mother’s breast cancer returned as metastatic while I was a young mother myself, I experienced the stretch of caring for two generations at…
Liked by Lane Weaver
-
Moderna went from viral genome to a clinical-grade vaccine batch in 42 days. In 2020. This is not theoretical. This week: Bundibugyo Ebola is a…
Moderna went from viral genome to a clinical-grade vaccine batch in 42 days. In 2020. This is not theoretical. This week: Bundibugyo Ebola is a…
Liked by Lane Weaver
-
Jason and I see the pros/cons of Chinese biotech sector differently but our community needs to debate this if we are to avoid having our policy…
Jason and I see the pros/cons of Chinese biotech sector differently but our community needs to debate this if we are to avoid having our policy…
Liked by Lane Weaver
-
Excited to share Episode 3 of Approved: Keytruda, Merck’s crown jewel immunotherapy. Alex Kesin and I trace the full history of pembrolizumab:…
Excited to share Episode 3 of Approved: Keytruda, Merck’s crown jewel immunotherapy. Alex Kesin and I trace the full history of pembrolizumab:…
Liked by Lane Weaver
-
At Convoke, we're building AI tools to help biopharma companies structure and operationalize biomedical knowledge. One challenge that our customers…
At Convoke, we're building AI tools to help biopharma companies structure and operationalize biomedical knowledge. One challenge that our customers…
Liked by Lane Weaver
Other similar profiles
Explore more posts
-
Prakash Raman
As we head into #JPM26 in San Francisco, I’m feeling incredibly energized by the momentum at InduPro Therapeutics. In just the past few weeks, we’ve announced two important collaborations that reinforce the strength of our platform—and the growing excitement around proximity-driven biology: Lilly partnered with InduPro in a program valued at up to $950M to develop up to three bispecific/trispecific oncology candidates. Using our proximity-guided platform, we will work with Lilly to create novel pairings of Tumor Associated Proximity Antigens (TAPAs) as co-targets with tumor-associated antigens to advance new cancer treatments. Sanofi made a strategic equity investment and entered a research collaboration with InduPro to advance our preclinical bispecific PD-1 agonist program for autoimmune and inflammatory disorders, including Sanofi-funded preclinical and IND-enabling work and a right of first negotiation. I want to thank our investors (The Column Group, Vida Ventures, Merck Ventures, Yosemite, Euclidean, Sanofi, Lilly) for their conviction in InduPro and the potential of our science, as well as our incredible team for their persistence, creativity, and focus on advancing breakthrough medicines for patients. We’re excited for all that lies ahead in 2026—and for what promises to be a busy and productive year. There’s more to come! We will be at the J.P. Morgan Healthcare Conference and hope to see you there! #Bispecifics #ProximalBiology #Lilly #Sanofi #JPM26
41 Comments -
Biotech Networks
SFBN Trending News: Galvanize Therapeutics raises $100 million in Oversubscribed Series C Financing to Transform the Treatment of Cancer and Chronic Lung Disease https://lnkd.in/gWdMasmr Sofinnova Partners leads premier investor syndicate backing Galvanize’s breakthrough pulsed electric field (PEF) platform—a first-of-its-kind, non-drug approach targeting solid tumors and chronic bronchitis, the leading cause of COPD. REDWOOD CITY, Calif., Sept. 3, 2025 /PRNewswire/ [...]
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Lane Weaver in United States
18 others named Lane Weaver in United States are on LinkedIn
See others named Lane Weaver